Latest Insider Transactions at X4 Pharmaceuticals, Inc (XFOR)
This section provides a real-time view of insider transactions for X4 Pharmaceuticals, Inc (XFOR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of X4 Pharmaceuticals, Inc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of X4 Pharmaceuticals, Inc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 11
2022
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
27,721
-22.92%
|
-
|
|
Sep 08
2021
|
Mary Di Biase Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,000
+22.99%
|
-
|
|
Aug 17
2021
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
13,448
-2.79%
|
$67,240
$5.1 P/Share
|
|
Aug 17
2021
|
Derek M Meisner Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
8,332
-10.28%
|
$41,660
$5.1 P/Share
|
|
Aug 17
2021
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,832
-8.22%
|
$54,160
$5.1 P/Share
|
|
Jul 15
2021
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
13,448
-2.71%
|
$67,240
$5.78 P/Share
|
|
Jun 30
2021
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,641
-1.96%
|
$15,846
$6.64 P/Share
|
|
Jun 24
2021
|
Derek M Meisner Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,166
-4.89%
|
$29,162
$7.0 P/Share
|
|
Jun 24
2021
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,417
-3.87%
|
$37,919
$7.01 P/Share
|
|
Jun 23
2021
|
Paula Ragan President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
44,826
+8.29%
|
-
|
|
Jun 23
2021
|
Derek M Meisner Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+12.79%
|
-
|
|
Jun 23
2021
|
Adam S. Mostafa Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,250
+10.41%
|
-
|
|
Jun 15
2021
|
Paula Ragan President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
44,826
+9.04%
|
-
|
|
Jun 15
2021
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,417
-4.2%
|
$37,919
$7.84 P/Share
|
|
Jun 15
2021
|
Adam S. Mostafa Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,250
+11.19%
|
-
|
|
Jun 15
2021
|
Derek M Meisner Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,166
-5.42%
|
$29,162
$7.84 P/Share
|
|
Jun 15
2021
|
Derek M Meisner Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+13.98%
|
-
|
|
Jun 02
2021
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
2,400
-0.59%
|
$21,600
$9.5 P/Share
|
|
Jun 01
2021
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
4,104
-0.99%
|
$36,936
$9.41 P/Share
|
|
May 03
2021
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
2,400
-0.58%
|
$19,200
$8.33 P/Share
|
|
Apr 05
2021
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
2,400
-0.57%
|
$21,600
$9.17 P/Share
|
|
Mar 24
2021
|
Derek M Meisner Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,728
+42.57%
|
-
|
|
Mar 24
2021
|
Paula Ragan President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
144,629
+25.73%
|
-
|
|
Mar 24
2021
|
Diego Cadavid Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,035
+50.0%
|
-
|
|
Mar 24
2021
|
Arthur Taveras Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,035
+50.0%
|
-
|
|
Mar 24
2021
|
Adam S. Mostafa Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
83,163
+42.45%
|
-
|
|
Mar 02
2021
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
2,400
-0.87%
|
$21,600
$9.74 P/Share
|
|
Feb 02
2021
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
2,400
-0.86%
|
$16,800
$7.88 P/Share
|
|
Jan 05
2021
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
2,400
-0.86%
|
$16,800
$7.0 P/Share
|
|
Dec 23
2020
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
4,800
-1.68%
|
$33,600
$7.0 P/Share
|
|
Oct 05
2020
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
1,797
-0.63%
|
$12,579
$7.0 P/Share
|
|
Oct 02
2020
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
603
-0.21%
|
$4,221
$7.0 P/Share
|
|
Nov 20
2017
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,868,966
+33.46%
|
$18,689,660
$10.0 P/Share
|
|
Nov 20
2017
|
Bill & Melinda Gates Foundation |
BUY
Conversion of derivative security
|
Direct |
722,179
+50.0%
|
-
|
|
Nov 20
2017
|
Gv 2016 Gp, L.L.C. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
451,362
+50.0%
|
-
|